Echo and natriuretic peptide guided therapy improves outcome and reduces worsening renal function in systolic heart failure: An observational study of 1137 outpatients.

[1]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[2]  G. Parati,et al.  Management of heart failure in the new era: the role of scores , 2016, Journal of cardiovascular medicine.

[3]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[4]  Patrizio Lancellotti,et al.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[5]  J. McMurray,et al.  Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction , 2016, European journal of heart failure.

[6]  Y. Pinto,et al.  Challenging the two concepts in determining the appropriate pre‐discharge N‐terminal pro‐brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels? , 2015, European journal of heart failure.

[7]  R. Latini,et al.  Understanding and making good use of changes in natriuretic peptide levels in chronic heart failure , 2015, European journal of heart failure.

[8]  R. McKelvie,et al.  Changes in N‐terminal pro‐B‐type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I‐Preserve study , 2015, European journal of heart failure.

[9]  W. Paulus,et al.  Heart failure with preserved ejection fraction: uncertainties and dilemmas , 2015, European journal of heart failure.

[10]  L. Tilson,et al.  Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study , 2015, European journal of heart failure.

[11]  R. D. de Boer,et al.  State of the Art: Newer biomarkers in heart failure , 2015, European journal of heart failure.

[12]  A. Bardají,et al.  A simple validated method for predicting the risk of hospitalization for worsening of heart failure in ambulatory patients: the Redin‐SCORE , 2015, European journal of heart failure.

[13]  V. Hasselblad,et al.  Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND‐HF , 2014, European journal of heart failure.

[14]  S. Solomon,et al.  Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial , 2015, European journal of heart failure.

[15]  P. McKie,et al.  The effects of dose reduction of furosemide on glomerular filtration rate in stable systolic heart failure. , 2014, JACC. Heart failure.

[16]  M. Pfisterer,et al.  Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure). , 2013, JACC. Heart failure.

[17]  Shawn A. Gregory,et al.  Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. , 2012, Journal of cardiac failure.

[18]  Shawn A. Gregory,et al.  Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. , 2011, Journal of the American College of Cardiology.

[19]  R. Califf,et al.  The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. , 2011, Journal of cardiac failure.

[20]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[21]  M. Prins,et al.  Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. , 2010, Journal of the American College of Cardiology.

[22]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[23]  C. Frampton,et al.  N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. , 2009, Journal of the American College of Cardiology.

[24]  Peter Buser,et al.  BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. , 2009, JAMA.

[25]  R. Doughty,et al.  Independence of restrictive filling pattern and LV ejection fraction with mortality in heart failure: An individual patient meta‐analysis , 2008, European journal of heart failure.

[26]  A. Cohen-Solal,et al.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.

[27]  G. Navis,et al.  Drawbacks and Prognostic Value of Formulas Estimating Renal Function in Patients With Chronic Heart Failure and Systolic Dysfunction , 2006, Circulation.

[28]  J. Cohn,et al.  Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. , 2006, Clinical chemistry.

[29]  L. Stevenson.  Hemodynamic Goals Are Relevant , 2006 .

[30]  R. Doughty,et al.  Pseudonormal mitral filling pattern predicts hospital re-admission in patients with congestive heart failure. , 2002, Journal of the American College of Cardiology.

[31]  P. Krishnaswamy,et al.  A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. , 2001, Journal of cardiac failure.

[32]  P. Giannuzzi,et al.  Reversible restrictive left ventricular diastolic filling with optimized oral therapy predicts a more favorable prognosis in patients with chronic heart failure. , 1998, Journal of the American College of Cardiology.

[33]  L. Stevenson,et al.  The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. , 1989, JAMA.

[34]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[35]  R. Troughton,et al.  Natriuretic peptide-guided heart failure management. , 2014, European heart journal.